Immunostimulants Market to Hit US$ 186.48 Billion by 2031 | Exclusive Report by Growth Plus Reports


Newark, New Castle, USA, June 15, 2023 (GLOBE NEWSWIRE) — The market analysis of the global immunostimulants market was conducted by Growth Plus Reports in 2022 and is valued at US$ 107.61 billion. The market is expected to hit a revenue CAGR of 6.3% to reach US$ 186.48 billion by 2031.

Analysis of the global market for immunostimulants indicates that during the forecast period, revenue share is likely to increase significantly. The global Immunostimulants Market is set to witness substantial growth in the coming years, fueled by the increasing demand for immune health boosters and the prevalence of infections and chronic diseases. A recently conducted market research report offers a comprehensive analysis of the current trends, market drivers, challenges, and growth opportunities in the field of immunostimulants.

Immunostimulants are substances that enhance the immune system’s response to fight against pathogens, boost immune defenses, and promote overall well-being. With the awareness emerging about the importance of a robust immune system in maintaining good health, the demand for immunostimulants has been witnessing significant growth.


Request a Sample Copy of the Research Report:

                                             Immunostimulants Market Scope

Report Attribute Details
Market Size Value in 2022 US$ 107.61 billion
Revenue Forecast in 2031 US$ 186.48 billion
CAGR 6.3%
Base Year for Estimation 2022
Forecast Period 2023 to 2031
Historical Year 2021
Segments Covered Product, Technology, Services, End User, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

The market research report highlights several factors contributing to the growth of the immunostimulants market. Firstly, the increasing incidence of infectious diseases, such as respiratory infections and viral outbreaks, leads to a surge in demand for products that can bolster the immune system. Additionally, the prevalence of chronic diseases, including cancer, autoimmune disorders, and cardiovascular diseases, has further propelled the need for immunostimulants to support immune function and disease management.

Furthermore, the aging population and the associated decline in immune function have also played a significant role in driving market growth. As individuals age, their immune system becomes less efficient, making them more susceptible to infections and diseases. Immunostimulants offer a promising solution to strengthen the immune response in older adults.

Competitive Landscape

A list of the prominent players operating in the global market for immunostimulants includes: 

  • Hoffmann-La Roche Ltd 
  • Johnson & Johnson 
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc. 

Market Segmentation: 

Based on type, the global immunostimulants market is segmented into vaccines, interferons, interleukins, colony-stimulating factors, and others. 

The vaccine segment is expected to account for a significant revenue share in the immunostimulants market. This is due to the prevalence of infectious diseases and cancer, which has increased the demand for immunostimulants.

Based on indication, the global immunostimulants market is segmented into cancer, immunodeficiency disorder, organ transplantation, chronic infection, and others.   

The immunostimulants market is predicted to expand faster in the North American area. Immunostimulants that can boost the body’s immune response and improve patient outcomes are in greater demand as chronic illnesses like cancer and autoimmune disorders become more common. 

Request for Customization –

Report Coverage 

Global market research on the immunostimulants market was done in-depth by Growth Plus Reports. We looked at the core market traits, noteworthy investment prospects, regional growth trends, ten-year revenue projections, rival market participants, and mergers and acquisitions.

In conclusion, the global immunostimulants market is expected to experience remarkable revenue growth in the coming years, driven by the increasing demand for immune health boosters and the rising prevalence of infectious and chronic diseases. With a focus on promoting immune system function and overall well-being, the market presents significant opportunities for both established market players and new entrants.

Table of Content

    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
    1. Vaccines         
    2. Interferons     
    3. Interleukins    
    4. Colony Stimulating Factors    
    5. Others
    1. Cancer                        
    2. Immunodeficiency Disorders             
    3. Organ Transplantations                     
    4. Chronic Infections      
    5. Others     


Buy this Premium Research Report:


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.


  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Schedule a call with our analyst:

Visit our report store at –

Browse more latest healthcare reports:

Glucose Elevating Agents Market by Products (Glucagon, Diazoxide), Indication (Hypoglycemia, Insulinoma), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), – Global Outlook & Forecast 2023-2031

Ergocalciferol Market by Application (Hypoparathyroidism, Rickets), Route of Administration (Oral, Injectable), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Leptin Based Therapeutics Market by Application (Obesity, Diabetes), Type (Recombinant Leptin, Leptin Receptor Agonists), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

ABCA4 Retinopathy Therapeutics Market by Drug Type (Anti-VEGF Drugs, LBS-008), Age Group (Children, Adults), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) – Global Outlook & Forecast 2023-2031

Tocolytic Agents Market by Drug Class (Magnesium Sulfate, Betamimetics), Route of Administration (Oral, Parenteral) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020”.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web:

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.